Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the champion healthcare stocks to bargain for 2026. On January 28, Truist Securities raised its terms people connected Teva Pharma (NYSE:TEVA) to $38 from $36 portion keeping a Buy rating, pursuing Q4 2025 results that included a $500 cardinal milestone payment. Although normalized gross missed estimates by astir 1%, Truist sees Teva’s maturation communicative arsenic intact, pointing to pipeline catalysts successful 2026 specified arsenic a imaginable FDA determination connected Olanzapine LAI, which could unlock a $3B income opportunity.

The steadfast besides expects biosimilars to enactment the generics concern contempt headwinds from gRevlimid income and tougher Austedo comparisons, noting Teva’s PEG ratio of 0.3 suggests charismatic worth comparative to growth.

The aforesaid time Teva Pharmaceutical Industries reported beardown Q4 2025 results, beating expectations with EPS of $0.96 versus $0.65 forecast and gross of $4.71 cardinal against $4.33 cardinal expected, aided by a $500 cardinal milestone outgo from Sanofi. Despite this, shares slipped arsenic Teva projected little 2026 gross of $16.4–$16.8 cardinal and adjusted EPS of $2.57–$2.77, reflecting a much than $1 cardinal deed from mislaid income of its generic Revlimid owed to rising competition.

The company’s innovative portfolio continues to thrust growth, with Austedo generating $725 cardinal successful U.S. income successful Q4, up 40% year-over-year, alongside contributions from Ajovy and Uzedy. Together, these 3 drugs delivered $3.1 cardinal successful 2025 gross and are expected to scope up to $3.6 cardinal successful 2026, underscoring Teva’s modulation from a generics-focused steadfast to a biopharma player. While near-term headwinds measurement connected guidance, halfway net are projected to rise, supported by expanding branded medicines and pipeline momentum.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is simply a planetary person successful generic and specialty medicines, specializing successful developing, manufacturing, and selling drugs crossed assorted therapeutic areas, including cardinal tense system, respiratory, and oncology.

While we admit the imaginable of TEVA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.